Contact us
  • Home
  • Resource
  • Why Develop Digital Therapeutics in Oncology?

Why Develop Digital Therapeutics in Oncology?

Oncology is the leading therapeutic area in the pharmaceutical market, representing around $273Bn and close to 20% of the total market share across all therapeutic areas, and is expected to see an increase in spending of more than $100Bn and the approval of close to 100 new oncology drugs in the next four years. However, innovative therapies are complex to administer, often with dosage and adherence issues, and have a potential dose-limiting effect. In oncology, digital therapeutics (DTx) can address these unmet needs and offer several benefits associated with patient self-management, such as increased satisfaction and trust, higher quality of life, reduced stress, and better understanding of personal responsibilities. In this article, we will review how digital therapeutics can enhance cancer patients experience with their treatment and illustrate it with concrete examples from our portfolio.

Fill out the form to access this content:

"*" indicates required fields

I consent that my personal data is stored and processed as described in theprivacy policy.*

This field is for validation purposes and should be left unchanged.

Why_Develop_digita_therapeutics_Oncology* to process your contact request. If you do not fill them in, your request cannot be processed. To find out more about the use of your personal data and how to exercise your rights, please consult the Privacy Policy

Back to top
Follow us: subscribe